InvestSMART

Alterity Therapeutics Limited (ASX: ATH) - Announcements

Current share price for ATH : $0.670 0.02 (3.08%)+

ASX company news and announcements for Alterity Therapeutics Limited (ATH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Alterity Therapeutics Limited (ATH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Alterity Therapeutics Limited (ATH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Alterity Therapeutics Limited (ATH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$146 Application for quotation of securities - ATH 1 Jul 2026 4:51PM $0.660 $0.670 risen by 1.52%
$146 Change in substantial holding 30 Jun 2026 8:16AM $0.570 $0.670 risen by 17.54%
$146 Change of Director's Interest Notice x 2 17 Jun 2026 11:54AM $0.580 $0.670 risen by 15.52%
$146 Corporate Presentation June 2026 16 Jun 2026 10:40AM $0.510 $0.670 risen by 31.37%
$146 Notification regarding unquoted securities - ATH 15 Jun 2026 2:41PM $0.480 $0.670 risen by 39.58%
$146 Notification of cessation of securities - ATH 15 Jun 2026 2:32PM $0.480 $0.670 risen by 39.58%
$146 Completion of Consolidation 12 Jun 2026 2:52PM $0.495 $0.670 risen by 35.35%
$146 Alterity and FDA Agree on Phase 3 Program for ATH434 in MSA 9 Jun 2026 9:01AM $0.009 $0.670 risen by 7,344.44%
$146 Share Consolidation Effective, Trading Under ATHDA 4 Jun 2026 9:49AM $0.009 $0.670 risen by 7,344.44%
$146 Change of Registered Office Address 3 Jun 2026 4:59PM $0.395 $0.670 risen by 69.62%
$146 Results of Meeting 29 May 2026 1:59PM $0.009 $0.670 risen by 7,344.44%
$146 Alterity Data Supports ATH434 Phase 3 Advancement in MSA 19 May 2026 10:02AM $0.010 $0.670 risen by 6,600%
$146 Corporate Presentation May 2026 12 May 2026 12:22PM $0.010 $0.670 risen by 6,600%
$146 Alterity Announces Publication on MRI as Biomarker for MSA 11 May 2026 9:25AM $0.011 $0.670 risen by 5,990.91%
$146 Alterity to Deliver Presentations at May Medical Meetings 7 May 2026 11:35AM $0.010 $0.670 risen by 6,600%
$146 Consolidation/Split - ATH 30 Apr 2026 11:45AM $0.010 $0.670 risen by 6,600%
$146 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2026 9:53AM $0.010 $0.670 risen by 6,600%
$146 Notice of General Meeting/Proxy Form 29 Apr 2026 12:54PM $0.009 $0.670 risen by 7,344.44%
$146 Alterity Receives Positive FDA Feedback on CMC Meeting 27 Apr 2026 8:56AM $0.010 $0.670 risen by 6,600%
$146 Change in substantial holding 24 Apr 2026 8:14AM $0.009 $0.670 risen by 7,344.44%
$146 Alterity Presents New Analysis of ATH434 Phase 2 Data at AAN 22 Apr 2026 9:57AM $0.011 $0.670 risen by 5,990.91%
$146 Initial Director's Interest Notice - Cunningham 21 Apr 2026 10:40AM $0.011 $0.670 risen by 5,990.91%
$146 Notification regarding unquoted securities - ATH 20 Apr 2026 7:06PM $0.010 $0.670 risen by 6,600%
$146 Notification regarding unquoted securities - ATH 20 Apr 2026 7:05PM $0.010 $0.670 risen by 6,600%
$146 Alterity Appoints Biotech Executive Ann Cunningham to Board 17 Apr 2026 9:54AM $0.008 $0.670 risen by 8,275%

1 - 25 of 544 results

Page 1 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.